Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Cabotegravir, Rilpivirine Drug Combination
DRUG
2 trials
Sponsors
University College, London
, University Paris 7 - Denis Diderot
Conditions
HIV Infections
HIV-1-infection
Hiv
Paediatric Human Immunodeficiency Virus Infection
Quality of Life
Phase 3
Long-Acting Treatment in Adolescents (LATA)
Active, not recruiting
NCT05154747
University College, London
Hiv, HIV-1-infection, HIV Infections +1
Start: 2023-06-22
End: 2026-03-31
Updated: 2024-04-29
Unknown Phase
Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine
Not yet recruiting
NCT06403865
University Paris 7 - Denis Diderot
Quality of Life
Start: 2024-05-31
End: 2026-10-31
Target: 280
Updated: 2024-05-08
Related Papers
Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.
2026-09-17
Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa.
2026-01-07
PA-257 ‘Nothing about us without us’: multi-country adolescent patient-led recruitment information in the long-acting treatment in adolescents (LATA) trial – an animated video to compliment ‘traditional’ participant information
2023-12-01